Group 1 - The board of directors of Chengdu Huasheng Technology Group Co., Ltd. held its 23rd meeting of the 13th session on August 1, 2025, with all 9 directors present, confirming compliance with relevant regulations [1][2] - The board approved the performance commitment completion report for Tibet Kangyu Pharmaceutical Co., Ltd., which reported a net profit of 16.78 million yuan for 2024, falling short of the promised 20 million yuan, leading to a cash compensation requirement from Tibet Wan'an Pharmaceutical Information Consulting Co., Ltd. [1][2] - The board approved the proposal to publicly transfer 51% of the equity of Tibet Kangyu, with a starting price based on asset evaluation at 63.78 million yuan, aiming to enhance the company's profitability and core competitiveness [2] Group 2 - The company scheduled its first extraordinary general meeting of shareholders for August 19, 2025, at 14:00, with all 9 votes in favor of the proposal [2]
华神科技: 第十三届董事会第二十三次会议决议公告